SOPHiA GENETICS Earnings Call Transcripts
Fiscal Year 2026
-
The company leverages a global, cloud-based AI platform for precision medicine, supporting rapid growth in genomic analysis and strong customer retention. Strategic partnerships, expanding applications, and a decentralized model drive revenue growth and position the firm for profitability by 2027.
-
Q1 2026 saw 22% revenue growth, record platform usage, and strong global expansion, with adjusted gross margin at 75.4% and net dollar retention up to 117%. Guidance for 2026 is reaffirmed, with growth expected to accelerate in the second half as new customers come online.
-
Leadership transition will bring a new CEO focused on commercial growth, with the founder moving to executive chairman. The company targets accelerated revenue growth through 2026, driven by U.S. market momentum, AI-powered platform differentiation, and expanding partnerships with leading academic centers.
Fiscal Year 2025
-
Revenue grew 19% in 2025 to $77.3M, with strong clinical and regional performance, improved margins, and record low churn. 2026 guidance targets 20%-22% revenue growth, margin expansion, and adjusted EBITDA breakeven by year-end, supported by major new contracts and product launches.
-
Q3 2025 saw 23% revenue growth, strong new customer signings, and robust expansion in liquid biopsy and biopharma partnerships. Guidance was raised, with continued operating leverage and a healthy pipeline supporting confidence in future growth.
-
Q2 2025 saw 16% revenue growth (20% excluding biopharma), record new customer signings, and a major multi-year AI partnership with AstraZeneca. Cash burn improved 35% year-over-year, and guidance for 2025 was reaffirmed, with strong momentum in clinical and rare disease segments.
-
Gross margin remains strong with ongoing expansion, and adjusted EBITDA profitability is targeted for 2027. U.S. growth is robust, driven by larger accounts and liquid biopsy adoption, while partnerships and a growing data asset support future pharma and AI opportunities.
-
Q1 2025 saw revenue up 13% year-over-year, record adjusted gross margin of 75.7%, and improved adjusted EBITDA loss. Strong new customer signings, U.S. growth, and expanded biopharma partnerships support reaffirmed 2025 guidance and a positive long-term outlook.
-
SOPHiA GENETICS presented its AI-driven, cloud-based platform's global adoption, highlighting rapid growth in the U.S. and new liquid biopsy offerings. The company targets 10%-17% revenue growth for 2025, with upside potential from biopharma and complex testing trends.
Fiscal Year 2024
-
2024 saw solid execution with $65.2M revenue, improved margins, and record new customer signings, despite biopharma headwinds. 2025 guidance calls for 10–17% revenue growth, driven by new applications and U.S. expansion, with profitability targeted by 2026.
-
The platform has expanded globally, processing over 1.8 million genomic profiles and launching new high-value applications like liquid biopsy and MSK-IMPACT. Financial performance is strong, with improved margins and cash position, and the company targets profitability by 2026 while expecting accelerated adoption and revenue growth from new offerings.
-
Q3 2024 saw clinical volume rebound and strong cost controls, with adjusted gross margin rising to 73.1% and cash burn down 39% year-over-year. Biopharma revenue remained weak, but new product launches and customer wins support a positive outlook, with full-year guidance reaffirmed.
-
U.S. bookings surged 40% in Q1, while biopharma faced 2024 challenges, prompting a shift to diversified, smaller deals and leadership changes. The cloud-based platform’s compatibility, data security, and multimodal capabilities drive adoption, with growth expected to normalize as bookings accelerate.
-
Q2 2024 saw revenue growth below expectations due to biopharma and EMEA headwinds, but gross margins and operating loss improved. Strategic actions, new product launches, and strong bookings position the business for reacceleration, with robust pipelines and a reaffirmed path to profitability.